Why Is Nektar Therapeutics Stock Surging Today?
Portfolio Pulse from Vandana Singh
Nektar Therapeutics Inc (NKTR) has announced that its former partner Eli Lilly And Co (LLY) presented incorrect data from two Phase 1b studies of its atopic dermatitis drug, rezpegaldesleukin (Rezpeg). The corrected data shows improved results, leading to a surge in NKTR's stock price. Nektar is planning to prioritize the development of Rezpeg, either in collaboration with Eli Lilly or independently.
August 07, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Eli Lilly's erroneous data on Nektar's drug, Rezpeg, has been corrected, showing improved results. This could potentially impact future collaborations between the two companies.
Eli Lilly's erroneous data on Nektar's drug, Rezpeg, has been corrected. This could potentially impact future collaborations between the two companies.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Nektar Therapeutics' stock price surged following the announcement of corrected data for its drug, Rezpeg. The company plans to prioritize the development of this drug.
The corrected data from Eli Lilly shows improved results for Nektar's drug, Rezpeg. This positive news has led to a surge in Nektar's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100